“We look at that as disappointing on the one hand because our job is to get medicines to patients,” Eli Lilly CEO David Ricks said at Semafor World Economy.
It really is wild what GLP1 agonists can treat. There’s evidence coming out that they can help with systemic inflammation issues, autoimmune issues, stuff like PCOS, etc.
My pet theory is that microplastics are causing a drop in natural GLP1 production.
It really is wild what GLP1 agonists can treat. There’s evidence coming out that they can help with systemic inflammation issues, autoimmune issues, stuff like PCOS, etc.
My pet theory is that microplastics are causing a drop in natural GLP1 production.